 |
|
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong
Korean J Intern Med. 2021;36(6):1450-1458. Published online 2021 Nov 1 DOI: https://doi.org/10.3904/kjim.2021.158
|
|
Citations to this article as recorded by
 Challenges in management of older patients with chronic myeloid leukemia
Jessica M. Stempel, Rory M. Shallis, Rong Wong, Nikolai A. Podoltsev
Leukemia & Lymphoma.2024; : 1. CrossRef Treatment-Free Remission in Chronic Myeloid Leukemia
Garrett Bourne, Ravi Bhatia, Omer Jamy
Journal of Clinical Medicine.2024; 13(9): 2567. CrossRef Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
Miriam Iezza, Sofia Cortesi, Emanuela Ottaviani, Manuela Mancini, Claudia Venturi, Cecilia Monaldi, Sara De Santis, Nicoletta Testoni, Simona Soverini, Gianantonio Rosti, Michele Cavo, Fausto Castagnetti
Cells.2023; 12(13): 1703. CrossRef Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia
Fang Cheng, Zheng Cui, Qiang Li, Liu Wang, Weiming Li
International Immunopharmacology.2023; 124: 110847. CrossRef Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China
Lixiao Song, Jun Guo, Dan Zhou, Shandong Tao, Banghe Ding, Liang Yu, Chunling Wang
Medicine.2023; 102(50): e36498. CrossRef Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication
Nur Hezrin Shahrin, Carol Wadham, Susan Branford
Current Hematologic Malignancy Reports.2022; 17(6): 171. CrossRef
|